Protocols›Cognitive & neurological›Neuroprotection
← Protocols
Clinically used overseas · CerebrolysinIn human trials · SS-31Combination not approved

Neuroprotection

Stack: Cerebrolysin + Semax + SS-31 · neuroprotection / recovery
"Two of the three carry genuine clinical mileage — Cerebrolysin is a registered medicine in dozens of countries, Semax in Russia. SS-31 is still in trials. The three together as a single neuroprotection stack has never been studied in anyone."
GoalNeuroprotection / recovery
Compounds3 · Cerebrolysin + Semax + SS-31
Humans exposed (est.)High (Cerebrolysin, Semax)
StatusCerebrolysin: registered / clinically used in ~50 countries · Semax: RU-registered · SS-31 (elamipretide): in human trials, not approved · MHRA (UK)/FDA (US): combination not approved
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Clinically used overseas
Where / who
Cerebrolysin is registered and used clinically in roughly 50 countries (Europe, Asia, Russia) for stroke, vascular dementia and TBI; Semax is a Russian-registered neuropeptide.
Use status
Decades of clinical use for both — large real-world exposure.
Evidence it adds
Real human exposure for two parts — trial results for Cerebrolysin are mixed/modest.
Basis: registration + clinical use abroad — strongest tier on this site
Combination not approved
Clinical record
No country lists this three-compound combination as an approved therapy.
Human trials
No trial has tested Cerebrolysin + Semax + SS-31 together. SS-31 (elamipretide) is itself still in trials and not approved anywhere.
Basis required for a clinical-use tag: none for the combination — absence shown, not hidden
Regulatory — read carefully
FDA (US)
None of the three is FDA-approved. SS-31 is in clinical development.
MHRA (UK)
Not licensed in the UK — all three sold as research material.
What it means
Overseas registration of Cerebrolysin/Semax is real public-use evidence, but is not MHRA/FDA approval.
Why it matters
UK pharmacovigilance does not cover them; SS-31 long-term human safety is still being established.
Basis: overseas registers (Cerebrolysin ~50 countries; Semax, Russia)
Why this combination

The logic is three different layers of neuroprotection: Cerebrolysin as a neurotrophic base (BDNF/GDNF-like activity, the strongest clinical record here), Semax for neuroprotective/cognitive support, and SS-31 targeting mitochondrial function. Each part has its own evidence; the combination has none, and SS-31 remains investigational. Strong free information, gated actionable depth.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake High

Cerebrolysin: ~50-country clinical use. Semax: Russian clinical use.

Human efficacy Mixed

Cerebrolysin RCTs modest/mixed; SS-31 trials ongoing; combination untested.

The honest ceiling

Two parts with real clinical mileage, one still in trials — but zero data on the three run together.

Fast facts
Compounds

Cerebrolysin · Semax · SS-31

Humans exposed (est.)

High (Cerebrolysin, Semax).

UK strip

GREEN — research material